EGFR-inhibitors in any line were used in approximately 80% of patients eligible to intensive therapy, irrespective of sidedness in RAS&BRAF wild-type tumours in line with the Swedish guidelines [2, 3]. This evidence concerns the gene BRAF and neoplasm.